NCT07079475View on ClinicalTrials.gov

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

DZD6008

DZD6008 will be administered orally at 40/60 mg QD or selected dose.

DRUG

Sunvozertinib

Sunvozertinib will be administered orally at 100 mg QD or selected dose.

DRUG

Osimertinib

Osimertinib will be administered orally at 80 mg QD

Sponsors
All Listed Sponsors
lead

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

INDUSTRY

NCT07079475 - Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | Biotech Hunter | Biotech Hunter